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Abstract
Background—Depression is prevalent in patients receiving hospice care. Standard 
antidepressant medications do not work rapidly enough in this setting. Evidence suggests that 
ketamine rapidly treats treatment refractory depression in the general population. Ketamine’s role 
for treating depression in the hospice population warrants further study.
Methods—A retrospective chart review of 31 inpatients receiving hospice care who received 
ketamine for depression on a clinical basis was conducted. The primary outcome measure was the 
Clinical Global Impression Scale, which was used retrospectively to rate subjects’ therapeutic 
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improvement, global improvement, and side effects from ketamine over 21 days. Additionally, 
time to onset of therapeutic effect was also analyzed.
Results—Using the CGI, ketamine was found to be significantly therapeutically effective 
through the first week after ketamine dosing (p < 0.05), with 93% of subjects showing positive 
results for days 0 – 3 and 80% for days 4 – 7 post ketamine dosing. Subjects experienced global 
improvement during all four time periods post ketamine dosing (all p-values < 0.05). Significantly 
more subjects had either no side effects or side effects that did not significantly impair functioning 
at each of the four assessed time periods post ketamine dosing (all p-values < 0.05). Additionally, 
significantly more subjects experienced their first therapeutic response during days 0–1 post 
ketamine dosing (p < 0.001) than during any other time period.
Conclusions—These data suggest that ketamine may be a safe, effective, and rapid treatment 
for clinical depression in patients receiving hospice care. Blinded, randomized, and controlled 
trials are required to substantiate these findings and support further clinical use of this medication 
in hospice settings.
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Introduction
Depression is one of the leading causes of disability worldwide (1) and is associated with 
increased morbidity and mortality (2–5). Standard antidepressants typically take four to six 
weeks to reach maximal effectiveness, and monotherapy with standard antidepressants is 
only effective approximately 35% of the time, often necessitating multiple trials of 
antidepressants (6, 7). Thus, there is mounting interest in possible treatments for depression 
that work more rapidly. This is especially true for populations with short prognoses, such as 
those receiving hospice care.
Psychostimulants, such as methylphenidate, are often used in hospice settings to rapidly 
treat depression, with some evidence to support this practice. (8–17) However, 
methylphenidate does not work for every patient, and its use can be limited by the 
development of anxiety, insomnia, agitation, and at times, mania. (18, 19)
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is another possible 
treatment. A growing body of literature, ranging from case reports to randomized controlled 
trials, supports the use of sub-anesthetic doses of intravenous (IV) infusions of ketamine at 
0.5 mg/kg over 4 hours to treat depressive symptoms in individuals with treatment resistant 
depression (20–37). Ketamine’s antidepressant properties are thought to be associated with 
its effects on the NMDA-receptor channel, glutamate transmission, mTOR-dependent 
synapse formation, cholinergic transmission, noradrenergic and serotonergic reuptake 
inhibition, as well as its interactions with other calcium and sodium channels (38–40).
Ketamine’s antidepressant properties are of great interest for patients receiving hospice care. 
Up to 42% of hospice patients have symptoms of depression. (41–43) Untreated depression 
in patients receiving hospice care is associated with significant morbidity and mortality. (44, 
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45) Since the average time patients received hospice care in the US in 2012 was around 10 
weeks, (with the median being less than 3 weeks)(46) and because standard pharmacologic 
treatments for depression take several weeks to reach maximal effect, many hospice patients 
will not live long enough to realize the benefits of standard treatments for depression. For 
these reasons, there is a growing interest in pharmacological treatments for depression with 
a rapid therapeutic effect such as ketamine.
Notably, a robust literature supports the safe and tolerable use of sub-anesthetic doses of 
ketamine for the treatment of pain in hospice patients (47–56). Furthermore, in both a small 
case series and an open label-trial, oral ketamine was found to be a fairly rapid, safe, and 
tolerable treatment for depression in patients receiving hospice care (57–59). In addition, 
these studies described a decrease in symptoms of anxiety with no insomnia or 
psychomimetic effects noted. In fact, most somatic symptoms improved.
Data from a retrospective chart review of the use of ketamine to clinically treat depression in 
patients receiving hospice care are presented in this paper. The objectives of this study are to 
provide preliminary data about the efficacy, tolerability, time to efficacy, duration of 
response, and side effects of ketamine for the treatment of depression in patients receiving 
hospice care. These results will inform future randomized controlled trials that are needed to 
definitively answer such questions.
Methods
The study was approved by the San Diego Hospice and The Institute for Palliative Medicine 
Institutional Review Board. Pharmacy data from 2005–2011 were used to identify patients 
who had received ketamine while being treated at an inpatient hospice care center. Thirty-
three patients were prescribed ketamine for depression and 31 of these received ketamine for 
the first time during their inpatient admission. A retrospective review of these 31 charts was 
conducted.
Inter-rater reliability was established using three charts (10%). Each of these three charts 
was reviewed by all three raters, two of whom were board certified psychiatrists and one of 
whom was a board certified palliative care specialist. For the remaining 26 charts, each chart 
was reviewed by one of these three raters.
Each chart was evaluated for 1) demographic variables, 2) psychiatric diagnoses and 
treatments, 3) ketamine dosage, route, and frequency of dose, 4) time to first response of 
depressive symptoms, 5) time to maximal response of depressive symptoms, 6) duration of 
response to ketamine, and 7) ketamine related side effects. Data was collected for pre-
determined time periods consisting of days 0–1, 2–3, 4–7, and 8–21 post-ketamine dosing. 
These time periods were chosen to capture possible rapid effects of ketamine, protracted 
effects, and longer-term effects based on the literature and our experience with an open-label 
trial. (58) In addition, we wanted to be vigilant about adverse events. Lastly, as this was a 
retrospective review, depression may not have been evaluated or commented on each day by 
the primary palliative care team.
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The Clinical Global Impression (CGI) scale was completed retrospectively based on 
palliative care team charting to evaluate subjects’ baseline clinical status pre-ketamine 
dosing and changes in the subjects’ clinical outcomes/side effects post-ketamine dosing. 
(60) CGI ratings were determined based on the notes regarding depression written by 
psychiatric consultants, primary physicians, nurses, and social workers each day of the 
inpatient admission prior to ketamine dosing and each day during the four assessment time 
periods, as available. Depression was not necessarily commented on in the charts each day 
for each patient.
Global improvement ratings on the CGI reflect improvement, whether or not the 
improvement is due entirely to the drug treatment and range from “very much improved” 
(score of 1) to “very much worse” (score of 7) with (1) very much improved; (2) much 
improved; (3) minimally improved; (4) no change; (5) minimally worse; (6) much worse; 
and (7) very much worse. Scores of 1–3 were categorized as positive outcomes and scores of 
5–7 were categorized as negative outcomes.
The Efficacy Index of the CGI has two components, the therapeutic effect and side effects, 
and is based specifically on the drug effect (i.e. response to ketamine). The therapeutic effect 
reflects how much the condition has improved related to the study medication and ranges 
from “unchanged or worse” (score of 1) to “marked” improvement (score of 4) with (1) 
unchanged to worse; (2) minimal; (3) moderate; and (4) marked improvement. Scores of 1 
were categorized as negative outcomes and scores of 2–4 were categorized as positive 
outcomes.
Side effect ratings on the CGI’s Efficacy of Index range from “none” (score of 1) to 
“outweighs therapeutic effect” (score of 4) with (1) none; (2) do not significantly interfere 
with patient functioning; (3) significantly interferes with patient functioning; and (4) 
outweighs therapeutic effect. Scores of 1–2 were categorized as positive outcomes and 
scores of 3–4 were categorized as negative outcomes.
Simple, formal, two-sided significance tests, based directly on binomial distribution and 
providing exact p – values, were performed for each CGI measure categorized into negative 
outcome versus positive outcome classifications and assumed as the null hypothesis that a 
subject had an equal chance of being classified in each.
For patients who only received one dose of ketamine, exact p – values, using a binomial 
distribution, were also obtained for the analyses of 1) time to first response, 2) time to 
maximal response, 3) time to fading of response, and 3) number of side effects, with the null 
hypothesis being that subjects had an equal chance of being in each cell (with the cells being 
the time periods of days 0–1, 2–3, 4–7, and 8–21 post-ketamine dosing for the analyses of 
“time to …”; and 0 side effects, 1 side effect, 2–3 side effects, and 4 or more side effects for 
“number of side effects”).
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Results
Sample
The sample was comprised of 11 male and 20 female subjects. The subjects ranged in age 
from 44 to 89 years, with a mean age of 68 years and a median age of 66 years (Table 1). 
The observed numbers of subjects for the CGI analyses were: 29 for days 0–1; 28 for days 
2–3; 20 for days 4–7; and 10 for days 8–21 post ketamine dosing respectively, except that 
only 28 patients were noted to be observed for side effects during the days 0–1 post 
ketamine dosing period.
Ketamine Dosing
Twenty two patients received a single dose of ketamine at 0.5 mg/kg, and five received a 
single 0.5 mg/kg dose followed by a single repeat dose of 0.5 mg/kg. Four received three 
times a day dosing each day they were studied, each dose again at 0.5 mg/kg. Twenty nine 
patients received an oral formulation of ketamine, one received a single oral dose followed 
by a single subcutaneous dose, and one received a single subcutaneous dose (Table 2).
Inter-rater Reliability
For measuring Global Improvement, the three raters had substantial agreement with Fleiss’s 
kappa = 0.65 (p < 0.001, 95% CI (0.45, 0.85)) and Kendall’s coefficient of concordance of 
0.99 (p = 0.002, 95% CI (0.91, 1)).
For the Efficacy Index, the three raters had almost perfect agreement with Fleiss’s kappa = 1 
(p < 0.001, 95% CI (0.80, 1)) and Kendall’s coefficient of concordance of 1 (p < 0.001, 95% 
CI (0.93, 1)).
Response to Ketamine
Therapeutic Effect Scale of the CGI—For the therapeutic effect rating on the CGI, 
positive therapeutic outcomes were more common than negative therapeutic outcomes at 
time periods days 0–1 (p < 0.001), days 2–3 (p < 0.001), and days 4–7 (p < 0.05) post dosing 
(Table 3a). Overall, ketamine was therapeutically effective through the first week post 
dosing. Figure 1A shows the therapeutic effect scale of the CGI outcomes, in which 93% of 
the patients showed positive results during days 0–3, 80% during days 4–7, and 60% during 
days 8–21 post dosing (Figure 1A).
Global Improvement Scale of the CGI—For the global improvement measure of the 
CGI, which assesses overall clinical improvement whether or not it was thought to relate to 
ketamine administration, positive therapeutic outcomes were more common than were 
negative therapeutic outcomes at all assessed time periods post ketamine dosing (p < 0.05 at 
days 0–1, 2–3, 4–7, and 8–21 post ketamine dosing) (Table 3b). Figure 1B shows the 
outcomes for the CGI global improvement scale, in which 52%, 46%, 55%, and 80% of the 
patients had positive global improvement over the respective four post dosing assessment 
periods and no patients were classified as “much worse” or “very much worse” at any time 
point.
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Time to First Response—Of the 22 subjects who received a single dose of ketamine, we 
were able to determine the time to first response for 14 subjects. Ten had their first response 
either on the day of ketamine dosing or day 1 post ketamine dosing and 4 had their first 
response on days 2–3 post ketamine dosing. None had their first response on days 4–21 post 
ketamine dosing. Significantly more subjects showed their first response on days 0–1 post 
ketamine dosing (p < 0.05) than at any other time point (Table 4).
Time to Maximum Response—Of the 22 subjects who received a single dose of 
ketamine, we were able to determine the time to maximum response for 11 subjects. 
Maximum response occurred for 4 subjects on days 0–1, 4 subjects on days 2–3, 2 subjects 
on days 4–7, and 1 subject on days 8–21 post ketamine dosing. There were no statistically 
significant differences indicating that maximal response occurred during one time period 
more commonly than any other (Table 4).
Fading of Response—Of the 22 subjects who received a single dose of ketamine, we 
were able to determine the time that the response started to fade for 6 subjects. The fading of 
response started in 5 subjects on days 2–3 and 1 subject on days 4–7 post ketamine dosing 
and was more common on days 2–3 post ketamine dosing (p < .05) than at any other time 
point (Table 4).
Side Effects
Side Effect Scale of the CGI—For the side effect measure of the CGI, the vast majority 
of subjects did not experience clinically significant side effects. More subjects had positive 
therapeutic outcomes (either no side effects or side effects that had no interference with 
functioning) than negative therapeutic outcomes (either significantly interfered with 
functioning or outweighed therapeutic effects) at all assessed time points post ketamine 
dosing (p < 0.001 at days 0–1 and 8–21 and p < 0.05 at days 2–3 and 4–7 post ketamine 
dosing) (Table 3c).
Figure 1C summarizes the data from the side effect scale of the CGI. Ninety-six percent, 
71%, 85%, and 100% had either no side effects or side effects which did not interfere with 
functioning over the respective four post dosing assessment periods.
Side Effect Descriptions—Of those who received a single dose of ketamine, 9 
experienced possible ketamine related side effects. All of the reported side effects were 
categorized as psychiatric: 7 subjects (45.5%) experienced disorientation, 4 (18.2%) had 
hallucinations, 4 (18.2%) had sedation, 1 (4.5%) had insomnia, 1 (4.5%) had delusions, and 
1 (4.5%) had anxiety. Three (13.6%) had only 1 side effect, and 6 (27.3%) had 2–3 
psychiatric side effects. Thirteen subjects (59.1%) had no side effects. Significantly more 
subjects had no side effects than any number of side effects (p < 0.05) (Table 4).
Discussion
This retrospective chart review represents a first step in providing preliminary data about the 
efficacy, tolerability, time to efficacy, duration of response, and side effects of ketamine for 
the treatment of depression in patients receiving hospice care. These results suggest the 
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utility of moving forward with randomized controlled trials. The overall findings support the 
potential for rapid efficacy and acceptable tolerability of ketamine in treating depression in 
this population. Ketamine, which was dosed orally the majority of the time, demonstrated 
rapid antidepressant properties, with efficacy typically occurring within 1 day of ketamine 
dosing.
The sustained effects of ketamine dosing were mixed. The vast majority of subjects in this 
study only received a single dose of ketamine and over half of those who experienced 
clinical benefit from ketamine started to show a fading of their response between days 2 and 
7 post ketamine dosing, which is consistent with findings in the literature. (20–37) However, 
a recent open label trial indicates that daily dosing is associated with minimal side effects 
and a more sustained effect (58). Further study is required to determine when and how 
frequently ketamine dosing should be repeated, and by what route.
Ketamine was well tolerated by the subjects in this study. Most subjects did not appear to 
experience any side effects from ketamine. When side effects were present, they were all 
categorized as psychiatric rather than somatic. This fits the findings from the open label trial 
(58), which suggested that side effects were rare and somatic symptoms often lessened after 
ketamine dosing. Ratings indicate that when side effects were present, they rarely interfered 
with functioning, suggesting that they were mild and likely tolerable. However, caution 
should be used when considering these results given the high propensity for delirium in this 
population. (61)
The vast majority of subjects received ketamine by the oral route. The effectiveness and 
safety of ketamine use might theoretically improve with oral administration due to first pass 
metabolism to norketamine (62). Importantly, oral dosing is much more practical and less 
invasive than is intravenous dosing in many patient populations, especially hospice 
populations. It can be administered in ambulatory care settings and does not require 
advanced hospital resources or the presence of anesthesia services. Furthermore, 
complications of intravenous catheter placement are numerous, especially in medically ill 
populations and include placement difficulty, diminishing site availability, need for site 
rotation every few days, infection, malfunction, thrombosis, and extravasation--all of which 
decrease comfort and increase the cost of care (63–65). The ability to effectively dose 
ketamine orally would be beneficial for all patients, especially those with serious medical 
illness and those who prefer to receive treatment in settings other than a hospital.
A chart review comes with natural limitations. It is not randomized, controlled, blinded or 
prospective in nature. Symptoms and diagnoses are not always documented consistently in 
the medical chart, nor are they documented in a scientifically rigorous way. One must thus 
take caution in generalizing the results of this study, both within the hospice population as 
well as to other patient populations. Another limitation of this particular study is the average 
hospice length of stay of the patients who were included exceeded national averages. Thus, 
these results may be less generalizable to typical hospice populations. However, these 
subjects still represent an important medically ill sample of patients who benefited from 
palliative care provided in a hospice setting and were in need of rapid amelioration of their 
depressive symptoms.
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Despite these limitations, the results of this exploratory chart review suggest that ketamine, 
which was most often orally administered, may be safe and effective for the rapid treatment 
of depression in a clinically diverse group of patients receiving hospice care. Further 
systematic study is needed to substantiate these results, as well as to determine the ideal 
dose, formulation, frequency of dosing, and clinical profile of patients who will best respond 
to and tolerate ketamine for the treatment of their depression.
A great need for a rapid acting antidepressant agent in patients receiving hospice care exists. 
This is a population that does not have time to wait for standard antidepressants to take 
effect. The treatment of depression has profound consequences on quality of life for both 
these patients and their families. This study helps set the stage for randomized controlled 
trials which can more definitively determine whether ketamine, which is inexpensive and 
easy to administer by multiple routes, may be an answer for this need.
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Figure 1. 
Figures 1A–C: Graphic summaries of the data. The four bars represent the four time periods 
post ketamine dosing and each bar goes from zero to 100 percent. Each bar designates 
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cumulative percentages going from the best to the worst category. Figure 1A is a graphic 
summary of the therapeutic index scale of the CGI and represents data from the best 
category of “marked improvement” to the worst category of “unchanged to worse”. Figure 
1B is a graphic summary of the global improvement scale of the CGI and represents data 
from the best category of “very much improved” to “very much worse”. Since no subjects 
were rated as “very much worse”, the worst category reflected in the figure is “minimally 
worse”. Figure 1C is a graphic summary of the side effects scale of the CGI and represents 
data from the best category of “none” to the worst category of “outweighs therapeutic 
effect”.
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Table 1
Demographics
Gender Number of Subjects
Male 11 (35.5%)
Female 20 (64.5%)
Age Years
Average 68
Median 66
Range 44 – 89
Marital Status Number of Subjects
Single 5 (16%)
Married 11 (35%)
Widowed 5 (16%)
Divorced 5 (16%)
Unknown 5 (16%)
Medical Diagnosis Number of Subjects
Neoplasm 24 (77%)
Coronary artery disease 1 (3%)
Liver failure 1 (3%)
Failure to Thrive 2 (6%)
Debility 3 (10%)
Length of Stay on Hospice Number of Days
Average 149
Median 89
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Table 2
Ketamine Dosing
Dosing Route Number of Subjects
Oral 29 (93.5%)
Subcutaneous 1 (3.2%)
Oral followed by Subcutaneous 1 (3.2%)
Dosing Number of Subjects
TID dosing 4 (12.9%)
Single dose 22 (71%)
Repeat single dose 5 (16.1%)
Single Dose of Ketamine = 0.5 mg/kg
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Table 3
Clinical Global Improvement Scale Results
A. Therapeutic Effect Scale of the CGI
Classification Days 0 – 1 Days 2 – 3 Days 4 – 7 Days 8 – 21
Positive outcome 27 26 16 6
Negative outcome 2 2 4 4
P - value < 0.001 < 0.001 < 0.05 > 0.05
B. Global Improvement Scale of the CGI
Classification Days 0 – 1 Days 2 – 3 Days 4 – 7 Days 8 – 21
Positive outcome 15 13 11 8
Negative outcome 3 4 2 0
P - value < 0.05 < 0.05 < 0.05 < 0.05
C. Side Effects Scale of the CGI
Classification Days 0 – 1 Days 2 – 3 Days 4 – 7 Days 8 – 21
Positive outcome 27 20 17 10
Negative outcome 1 8 3 0
P - value < 0.001 < 0.05 < 0.05 < 0.001
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